![Samuel Kintz](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Samuel Kintz
Gründer bei
ENLIVEN THERAPEUTICS, INC.
Vermögen: 38 Mio $ am 31.08.2026
Profil
Samuel S.
Kintz is the founder of Enliven Therapeutics, Inc., founded in 2019, where the title held is Head-Pipeline.
Mr. Kintz is also the founder of Enliven Therapeutics, Inc...
Mr. Kintz was Senior Director-Strategy & Business Development at Stemcentrx, Inc. from 2016 to 2019.
Mr. Kintz was Head-Research at AbbVie Stemcentrx LLC from 2016 to 2019.
Mr. Kintz was Head-Medicinal Chemist at Genentech, Inc. Mr. Kintz was Vice President-Business Development & Applications at BlueLight Therapeutics, Inc. Mr. Kintz completed undergraduate and MBA degrees at Stanford University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2026 | 652’892 ( 0.89% ) | 38 Mio $ | 31.08.2026 |
Aktive Positionen von Samuel Kintz
| Unternehmen | Position | Beginn |
|---|---|---|
| ENLIVEN THERAPEUTICS, INC. | Gründer | 01.06.2019 |
Enliven Therapeutics, Inc. /US/
 Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology Engages in discovery and development of small molecule treatments for cancer | Gründer | - |
Ehemalige bekannte Positionen von Samuel Kintz
| Unternehmen | Position | Ende |
|---|---|---|
AbbVie Stemcentrx LLC | Corporate Officer/Principal | 01.06.2019 |
Stemcentrx, Inc.
 Stemcentrx, Inc. BiotechnologyHealth Technology Develops life-changing therapies for cancer patients | Corporate Officer/Principal | 01.06.2019 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | - |
BlueLight Therapeutics, Inc.
 BlueLight Therapeutics, Inc. BiotechnologyHealth Technology Develops novel systems to analyze real-time protein function for research and clinical applications | Corporate Officer/Principal | - |
Ausbildung von Samuel Kintz
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
18
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
BlueLight Therapeutics, Inc.
BlueLight Therapeutics, Inc. BiotechnologyHealth Technology Develops novel systems to analyze real-time protein function for research and clinical applications | Health Technology |
Stemcentrx, Inc.
Stemcentrx, Inc. BiotechnologyHealth Technology Develops life-changing therapies for cancer patients | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AbbVie Stemcentrx LLC | |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology Engages in discovery and development of small molecule treatments for cancer | Health Technology |
Enliven Therapeutics, Inc.
 Enliven Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage precision oncology company that develops molecule therapies | Health Technology |
